Anzeige
Erschienen in:
01.02.2009 | Letter to the Editor
Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2009
Einloggen, um Zugang zu erhaltenAbstract
Numerous studies referring to conventional chemotherapy for aggressive fibromatosis with the use of doxorubicin, cyclophosphamide, vincristin, vinblastine and other drugs have been published. Imatinib mesylate is a recently developed oral anticancer agent designed to selectively inhibit tyrosine kinases implicated in oncogenesis and it seems to represent a promising opportunity (also in first line) in the treatment of patients with advanced disease not candidate to prior surgery.